Erasca Faces Shareholder Lawsuit Over Drug Data Disclosures

Investors who experienced substantial losses in Erasca, Inc. (NASDAQ: ERAS) stock have until August 10, 2026, to apply to lead a shareholder class action lawsuit alleging securities law violations related to the company's oncology drug candidate ERAS-0015.

The lawsuit, filed in the U.S. District Court for the Southern District of California, charges Erasca and certain of its top executives with making allegedly false and misleading statements and failing to disclose material information during the class period. The core of the allegations centers on the company's clinical-stage precision oncology therapies.

Class action filings claim that preclinical data for ERAS-0015 was based on improper comparisons to competitors and may have infringed on patent and trade secret protections. Investors allege that Erasca lacked a reasonable basis for its positive statements concerning ERAS-0015.

Erasca's stock price dropped significantly in late April 2026. On April 27, the company disclosed it had received a letter from Revolution Medicines, Inc. asserting that ERAS-0015 infringes on a patent and involves trade secret misappropriation. This news caused Erasca's stock to fall nearly 11%. Later that day, Erasca reported preliminary Phase I data for ERAS-0015, including a patient death, and noted that comparisons to other product candidates were based on cross-study analyses, not head-to-head trials. Following this update, the stock price declined by over 48%.

The lawsuit seeks to represent purchasers of Erasca common stock during the specified period. The lead plaintiff role allows an investor to direct the litigation and select legal counsel. An investor's ability to share in any potential recovery is not dependent on serving as lead plaintiff.